Allarity Therapeutics

Allarity Therapeutics Unveils Novel Predictive Tool for Daratumumab Response in Multiple Myeloma Patients

a month ago

• Allarity Therapeutics has developed a new Drug Response Predictor (DRP®) for daratumumab that can identify multiple myeloma patients most likely to benefit from treatment, as presented at AACR 2025. • The daratumumab DRP® is based on 53 genes associated with treatment sensitivity or resistance, and has demonstrated ability to predict treatment outcomes and survival in clinical samples. • This marks Allarity's first DRP® for an antibody therapy, expanding beyond small-molecule drugs and positioning the company for potential strategic partnerships in precision oncology.

CHOSA's Platinum Drug Response Predictor Shows Promise in Personalizing Cancer Treatment

2 months ago

• CHOSA will release results from a blinded retrospective study predicting cisplatin efficacy in lung cancer patients from the SPLENDOUR trial by the end of Q2 2025, potentially revolutionizing treatment selection. • The company's Drug Response Predictor (DRP) for platinum drugs demonstrated significant clinical value in breast cancer, where a 50% difference in DRP score corresponded to a three-fold difference in carboplatin treatment benefit. • CHOSA's predictive technology could enhance the efficacy of platinum-based therapies across multiple cancer types and improve outcomes when combined with immunotherapy, addressing a critical need in the $60 billion PD-1/PD-L1 market.

Pipeline Progress: Over 25 New Therapies in Development for Metastatic Liver Cancer

2 months ago

• DelveInsight's latest report reveals a robust pipeline with over 20 companies developing 25+ therapies for metastatic liver cancer, offering new hope for patients with limited treatment options. • Several promising clinical trials are underway in 2025, including studies evaluating novel combinations such as AK104 plus lenvatinib, tislelizumab with lenvatinib, and triplet therapy of nivolumab, relatlimab and bevacizumab. • Key emerging therapies include exoASO-STAT6 targeting tumor-associated macrophages, STP705 dual TGF-ß1/COX-2 inhibitor, and ONCR-177, an oncolytic viral immunotherapy expressing five transgenes to fight tumors through multiple mechanisms.

Pipeline Analysis Reveals 85+ Drugs in Development for Metastatic Prostate Cancer Treatment

3 months ago

• DelveInsight's comprehensive analysis identifies over 80 pharmaceutical companies actively developing 85+ pipeline drugs for metastatic prostate cancer treatment. • Novel therapies in development include TAVT-45, a reformulated abiraterone acetate, and Onvansertib, a first-in-class PLK1 inhibitor, demonstrating innovation in treatment approaches. • Multiple clinical trials are underway, including Phase III studies by major players like Bayer, AstraZeneca, and Novartis, evaluating new treatment combinations and targeted therapies.

Advancements in Gastrointestinal Stromal Tumors Treatment Pipeline

4 months ago

Recent developments in the Gastrointestinal Stromal Tumors (GIST) treatment pipeline highlight significant progress, with over 25 companies actively developing more than 28 pipeline drugs. Key players like Jiangsu Hengrui Medicine, Novartis, and Daiichi Sankyo Company are advancing promising therapies, including Famitinib, Nilotinib, and DS 6157, through various stages of clinical trials.

Allarity Therapeutics Advances Stenoparib for Ovarian Cancer with Phase 2 Trial Expansion

6 months ago

• Allarity Therapeutics is expanding its Phase 2 clinical trial of stenoparib for advanced ovarian cancer, aiming to optimize dosing and patient selection. • The trial focuses on patients with platinum-resistant disease who have shown durable clinical benefit from stenoparib in earlier phases. • Enrollment for the expanded Phase 2 trial is set to begin in the first half of 2025 at leading U.S. trial sites, with potential UK sites. • Stenoparib's impact on the Wnt pathway will be evaluated, potentially differentiating it in the PARP inhibitor market.

Allarity Therapeutics' Stenoparib Shows Promise in Advanced Ovarian Cancer Phase 2 Trial

6 months ago

• Allarity Therapeutics reports that two patients with advanced ovarian cancer have remained on stenoparib treatment for over 14 months in a Phase 2 trial. • The company's strong financial position, with $18.5 million in cash, supports the advancement of stenoparib towards potential FDA registration. • Allarity's medical laboratory has expanded its services to external biotech clients, generating revenue through gene expression and diagnostic capabilities. • Stenoparib's unique mechanism of action, inhibiting PARP1/2 and tankyrase 1/2, continues to show potential in heavily pretreated ovarian cancer patients.